Compositions and methods involving an essential Staphylococcus aureus gene and its encoded protein
US6376652B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Dec 22, 1999 |
| Grant date | Apr 23, 2002 |
| Priority date | — |
| Expiry date | Dec 22, 2019 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2795/10043
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to newly identified polynucleotides and polypeptides, and their production and uses, as well as their variants, agonists and antagonists, and their uses. In particular, the invention relates to polynucleotides and polypeptides of a Staphylococcus aureus (S. aureus) DnaI related protein, as well as its variants, hereinafter referred to as “S. aureus DnaI”, “S. aureus DnaI polypeptide(s)”, and “S. aureus dnaI polynucleotides” as the case may be. Also, the invention relates to a specific interaction between the S. aureus DnaI related protein and a growth-inhibitory protein encoded by the S. aureus bacteriophage 77 genome. The phage ORF product interacts with the S. aureus DnaI polypeptide, and the invention contemplates use of this interaction target site for the basis of a drug screening assay. In addition, the invention relates to polynucleotides and polypeptides of a protein complex containing S. aureus DnaI and DnaC related proteins, as well as their variants.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.